Published in Clinical Trials Week, December 3rd, 2007
"By March 2003, the compound was in phase IIb/ III trials for the prevention of deep vein thrombosis. By November 2005, a phase III trial had been initiated for the prevention of stroke and embolism due to atrial fibrillation and in May 2006 phase III trials for the prevention of secondary venous thromboembolism began," wrote M. Ieko and colleagues, Hokkaido University.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.